Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 20;13(1):96.
doi: 10.3390/vaccines13010096.

Impact of HPV Catch-Up Vaccination on High-Grade Cervical Lesions (CIN2+) Among Women Aged 26-30 in Northern Norway

Amanda Sørensen Jørgensen  1 , Gunnar Skov Simonsen  1   2 , Sveinung Wergeland Sørbye  3
Affiliations

Impact of HPV Catch-Up Vaccination on High-Grade Cervical Lesions (CIN2+) Among Women Aged 26-30 in Northern Norway

Amanda Sørensen Jørgensen et al. Vaccines (Basel). .

Abstract

Background/objectives: Human papillomavirus (HPV) is the primary cause of high-grade cervical lesions and cervical cancer worldwide. In Norway, HPV vaccination was introduced in 2009 for seventh-grade girls and extended through a catch-up program from 2016 to 2019 for women born between 1991 and 1996. This study evaluates the impact of the catch-up vaccination program on the incidence of HPV and high-grade cervical lesions in Troms and Finnmark.

Methods: We analyzed data from 40,617 women aged 26 to 30 who underwent cervical screening between 2009 and 2023 in Troms and Finnmark, including 1850 women with high-grade cervical lesions (CIN2+) on biopsy. Using linear regression, we assessed trends in high-grade lesion incidence per 1000 screened women and the association between vaccination status and HPV-16/18 incidence.

Results: Between 2017 and 2023, the incidence of high-grade cervical lesions significantly decreased: CIN2+ decreased by 33.4%, and CIN3+ decreased by 63.4%. Significant reductions in HPV-16/18-associated high-grade cervical lesions were observed among vaccinated women, with the proportion of CIN2+ cases due to HPV-16 and 18 decreasing from 56.8% in 2017 to 40.7% in 2023, reflecting a 55.8% reduction in the absolute number of cases caused by these high-risk HPV types. Comparing unvaccinated women aged 25-26 in 2016 and vaccinated women in 2023, HPV-16 incidence decreased from 5.1% to 0.1%, and HPV-18 incidence decreased from 3.3% to 0.0%.

Conclusions: The catch-up vaccination program significantly reduced the incidence of HPV-16/18 and high-grade cervical lesions in Troms and Finnmark, even with the lower vaccination coverage observed in the catch-up program. These findings demonstrate the effectiveness of HPV vaccination programs in reducing HPV infections and associated cervical lesions.

Keywords: HPV epidemiology; HPV types 16 and 18; HPV vaccination; Norway; catch-up immunization; cervical cancer prevention; cervical intraepithelial neoplasia (CIN); cervical screening programs; public health impact; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Incidence of CIN2+ per 1000 screened women aged 26–30 in Troms and Finnmark (2009–2023). Linear regression analysis demonstrates statistically significant trends with p < 0.01 for both periods, 2009–2017 and 2017–2023. For details on the proportions of women belonging to vaccinated cohorts during these years, please refer to Table 2.
Figure 2
Figure 2
Incidence of CIN3+ per 1000 screened women aged 26–30 in Troms and Finnmark (2009–2023). Linear regression analysis demonstrates statistically significant trends with p < 0.05 for the period 2009–2017 and p < 0.01 for 2017–2023. For details on the proportions of women belonging to vaccinated cohorts during these years, please refer to Table 2.
Figure 3
Figure 3
Incidence of cervical cancer per 1000 screened women aged 26–30 in Troms and Finnmark (2009–2023). Linear regression analysis demonstrates no statistically significant trends, with p > 0.05 for both the periods 2009–2017 and 2017–2023. For details on the proportions of women belonging to vaccinated cohorts during these years, please refer to Table 2.
Figure 4
Figure 4
Incidence of HPV-16/18 and other HPV types from 2017–2023 among women with CIN2+ aged 26–30 years in Troms and Finnmark. For details on the proportions of women belonging to vaccinated cohorts during these years, please refer to Table 2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Plotzker R.E., Vaidya A., Pokharel U., Stier E.A. Sexually Transmitted Human Papillomavirus: Update in Epidemiology, Prevention, and Management. Infect. Dis. Clin. N. Am. 2023;37:289–310. doi: 10.1016/j.idc.2023.02.008. - DOI - PubMed
    1. Khan M.S., Savoy M. Impact of Human Papillomavirus Vaccination in Reducing Cancer. Prim. Care. 2020;47:529–537. doi: 10.1016/j.pop.2020.05.007. - DOI - PubMed
    1. Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., Arbyn M., Basu P., Bray F., Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob. Health. 2023;11:e197–e206. doi: 10.1016/S2214-109X(22)00501-0. - DOI - PMC - PubMed
    1. Norwegian Cancer Registry Cancer in Norway 2023. 2023. [(accessed on 1 January 2025)]. Available online: https://www.kreftregisteret.no/Generelt/Rapporter/Cancer-in-Norway/cance...
    1. World Health Organization Cervical Cancer Elimination Initiative: Strategy. (n.d.) [(accessed on 22 December 2024)]. Available online: https://www.who.int/initiatives/cervical-cancer-elimination-initiative/s....

LinkOut - more resources